
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fibroblast Spheroids
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
FibroBiologics Reports IND-Enabling Data Showing Promise of Fibroblast Spheroids
Details : Company announced positive IND-enabling updates from its psoriasis research program demonstrating potential of human dermal fibroblast (HDF) spheroids as a novel therapeutic approach for psoriasis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 11, 2025
Lead Product(s) : Fibroblast Spheroids
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Podiatry
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CYWC628 (Fibroblast Spheroids) Safety & Efficacy In Refractory Diabetic Foot Ulcers vs SOC
Details : This drug candidate is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Diabetic Foot.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 31, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Podiatry
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CYPS317
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Yorkville
Deal Size : $25.0 million
Deal Type : Financing
FibroBiologics Announces $25 Million Financing
Details : The financing is intended to support the clinical development of CYPS317, currently being evaluated for the treatment of psoriasis.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
December 23, 2024
Lead Product(s) : CYPS317
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Yorkville
Deal Size : $25.0 million
Deal Type : Financing

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CYWC628
Therapeutic Area : Podiatry
Study Phase : Preclinical
Recipient : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Collaboration
FibroBiologics and Charles River Partner for Fibroblast Cell-Based Therapies
Details : The collaboration aims to develop and manufacture FibroBiologics’ therapeutic master cell bank, working cell bank, and fibroblast-based spheroids product, CYWC628, for diabetic foot ulcer (DFU).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
October 18, 2024
Lead Product(s) : CYWC628
Therapeutic Area : Podiatry
Highest Development Status : Preclinical
Recipient : Charles River Laboratories, Inc
Deal Size : Undisclosed
Deal Type : Collaboration

Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
Details : Tolerogenic Fibroblasts is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 15, 2021

 Reset All
Reset All